Same Drug Class

Ipilimumab vs Tofacitinib

Ipilimumab vs Tofacitinib: Overview

This comparison examines the pharmacological differences between Ipilimumab and Tofacitinib.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days; Tofacitinib — 3.2 hours.

Chemical Properties

Molecular Formula: Tofacitinib — C16H20N6O.

Molecular Weight: Tofacitinib — 312.3700 g/mol.

Type: Ipilimumab — Antibody; Tofacitinib — Small molecule.